United States v. Moffett

53 F.4th 679
CourtCourt of Appeals for the First Circuit
DecidedNovember 18, 2022
Docket22-1075P
StatusPublished
Cited by2 cases

This text of 53 F.4th 679 (United States v. Moffett) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Moffett, 53 F.4th 679 (1st Cir. 2022).

Opinion

United States Court of Appeals For the First Circuit

No. 22-1075

UNITED STATES OF AMERICA,

Appellee,

v.

MARK MOFFETT,

Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. William D. Young, U.S. District Judge]

Before

Barron, Chief Judge, Lynch and Gelpí, Circuit Judges.

Michael Pabian, with whom Martin G. Weinberg was on brief, for appellant. Karen L. Eisenstadt, Assistant United States Attorney, with whom Rachael S. Rollins, United States Attorney, was on brief, for appellee.

November 18, 2022 BARRON, Chief Judge. Mark Moffett was charged in 2019

in the United States District Court for the District of

Massachusetts with nine counts of wire fraud and six counts of

aggravated identity theft for his participation in an alleged

health insurance fraud scheme. After a ten-day jury trial, he was

convicted on all counts. Moffett contends in this appeal that the

convictions must be vacated on a number of distinct grounds,

including the one that we conclude is decisive -- namely, that the

verdict form that was submitted to the jury violated Moffett's

federal constitutional right to a jury trial by expressly referring

to certain trial exhibits that the government alone selected while

not otherwise referring to any of the evidence in the case.

I.

Moffett joined Aegerion, a Cambridge, Massachusetts-

based pharmaceutical company, as a sales representative in 2014.

The company at that time promoted and sold a cholesterol-lowering

drug, "Juxtapid." The sticker price for Juxtapid was as high as

several hundreds of thousands of dollars per patient, per year.

For each "sale" of the drug, sales representatives for Aegerion

like Moffett received a bonus.

The U.S. Food and Drug Administration ("FDA") as of that

time had approved Juxtapid only for the treatment of a specific

disease, homozygous familial hypercholesterolemia ("HoFH"). Many

health insurance companies in turn had approved coverage for

- 2 - Juxtapid only if it had been prescribed to a patient to treat a

qualifying HoFH diagnosis. Moffett often assisted doctors and

their offices with completing health insurance paperwork,

including documents necessary to demonstrate the requisite

indication of such a diagnosis so that a prescription for Juxtapid

would be covered by the patient's insurance.

In 2019, a federal grand jury in the District of

Massachusetts indicted Moffett on nine counts of wire fraud under

18 U.S.C. § 1343 and six counts of aggravated identity theft under

18 U.S.C. § 1028A. 1 The indictment alleged that Moffett

"devised . . . a scheme and artifice to defraud, and to obtain

money from health insurance companies to pay [Aegerion] for

[Juxtapid] by falsely representing that patients for whom doctors

had prescribed [the drug] met the health insurance companies'

coverage criteria."

1 The wire fraud statute, 18 U.S.C. § 1343, provides that "[w]hoever, having devised or intending to devise any scheme or artifice to defraud, or for obtaining money or property by means of false or fraudulent pretenses, representations, or promises, transmits or causes to be transmitted by means of wire . . . communication in interstate or foreign commerce, any writings . . . for the purpose of executing such scheme or artifice, shall be fined under this title or imprisoned not more than 20 years, or both." The aggravated identity theft statute, 18 U.S.C. § 1028A, as relevant here, provides that "[w]hoever, during and in relation to [a wire fraud offense], knowingly . . . uses, without lawful authority, a means of identification of another person shall, in addition to the punishment provided for such felony, be sentenced to a term of imprisonment of 2 years."

- 3 - A ten-day jury trial was held in the District of

Massachusetts in December 2019. The government introduced

evidence at trial of communications that it claimed included false

statements about patient diagnoses that had been submitted to

health insurers to obtain reimbursement from them for

prescriptions for Juxtapid. The government also put on witnesses

-- including five doctors and some of their staff members -- to

show that Moffett made or caused those false statements to be made

regarding the diagnoses of the patients for whom Juxtapid had been

prescribed and for which reimbursement from the health insurers

had been sought.

According to the government, Moffett's alleged false

statements on the insurance documents were communicated to health

insurers through "wires." 18 U.S.C. § 1343. The government also

alleged that Moffett included the doctors' identifying information

on some of those documents in a manner that constituted the

unauthorized "uses" of that identifying information for purposes

of the federal statute that makes identity theft a crime. 18

U.S.C. § 1028A.

Moffett introduced evidence at trial of email exchanges

with doctors that he argued demonstrated that they were aware of

the only approved use of Juxtapid and that he did not actually

encourage "off label" prescriptions for that drug. He also

elicited testimony for the purpose of impugning the credibility of

- 4 - the witnesses whose testimony tended to suggest that Moffett added

false information or signatures to insurance letters and

authorization forms. He further introduced evidence that sought

to show that at least some of the doctors personally approved and

signed the allegedly fraudulent documents.

On the second day of trial, after the jury had been

dismissed, the District Court informed the parties that it had

been working on a verdict form to give to the jury that would

"organize[] the case in a logical foundation." The next day the

District Court provided the parties with the draft verdict form

and invited the government to select an exhibit that constituted

the alleged "wire" for each of the wire fraud counts, as well as

an exhibit that constituted the alleged "use" for each of the

"identity theft" counts, so that the selected exhibit could be

identified on the verdict form in relation to the relevant count.

The government obliged.

Moffett objected both orally and in a written filing to

the proposed verdict form insofar as it would reference the

government-selected exhibits. 2 Moffett argued that if the

District Court submitted to the jury such a verdict form, then the

District Court would be "invading the province of the jury to

2 Moffett also objected to the District Court's decision to re-order the counts on the verdict form, but he does not press that theory of error on appeal, and we therefore do not address it.

- 5 - deliberate how it wants to deliberate and . . . relieving the

government of [its] burden" to "identify and prove which

communications are the subject of the various counts in the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Medina
First Circuit, 2025

Cite This Page — Counsel Stack

Bluebook (online)
53 F.4th 679, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-moffett-ca1-2022.